Drug Profile
Research programme: HDV type 2 diabetes mellitus therapeutic - Diasome Pharmaceuticals
Alternative Names: Oral HDV + novel T2DM candidateLatest Information Update: 25 Aug 2023
Price :
$50
*
At a glance
- Originator Diasome Pharmaceuticals
- Class
- Mechanism of Action Glucose modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Type 2 diabetes mellitus
Most Recent Events
- 25 Aug 2023 Preclinical development of HDV type 2 diabetes mellitus therapeutic for Type 2 diabetes mellitus is underway in the US (Diasome Pharmaceuticals pipeline, August 2023)
- 11 Dec 2015 Preclinical trials in Type-2 diabetes mellitus in USA (PO)